Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(b) and (e)
On January 10, 2022, Foghorn Therapeutics Inc. (the "Company") entered into a
transition agreement with Carl Decicco (the "Transition Agreement"). Under the
Transition Agreement, Dr. Decicco will step down from his position as Chief
Scientific Officer of the Company effective as of January 10, 2022, will serve
as Special Advisor to the Company's newly appointed Chief Scientific Officer
through January 31, 2022 and will retire from the Company on January 31, 2022
(the "Separation Date"). Dr. Decicco will continue to receive his current base
salary through the Separation Date and will be eligible to receive an annual
bonus based on the achievement of the pre-established performance objectives in
respect of fiscal year 2021. Under the Transition Agreement, any vested stock
options held by Dr. Decicco as of the Separation Date will remain exercisable
until July 5, 2022.
On this same date, the Company announced that Steven Bellon, PhD. had been
appointed to serve as the Company's Chief Scientific Officer, effective as of
January 10, 2022.
Dr. Bellon joined Foghorn Therapeutics in 2016 as head of drug discovery,
bringing more than 20 years of drug discovery experience from multiple drug
classes. Prior to joining Foghorn, Mr. Bellon was executive director and head of
structural biology, and lead discovery and project management at Constellation
Pharmaceuticals. Prior to his work at Constellation, he held positions of
increasing responsibility at Amgen and Vertex Pharmaceuticals. Dr. Bellon
received a Ph.D. in physical chemistry from MIT under the direction of Stephen
Lippard and then completed postdoctoral training at Yale University with Thomas
Steitz, Nobel Laureate, funded by a Damon Runyon fellowship.
The foregoing description of the Transition Agreement does not purport to be
complete and is qualified in its entirety by reference to the full text of the
agreement, which agreement will be filed as an exhibit to the Company's next
Form 10-K.

© Edgar Online, source Glimpses